U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07467317) titled 'BV-CHP Real-life and Biological Evidences in Patients With sALCL' on Feb. 26.
Brief Summary: Systemic Anaplastic Large Cell Lymphomas (sALCL) are rare lymphomas for which the cooperation in the collection of biological and clinical data is necessary to improve knowledge on the disease. The addition of a targeted therapy to chemotherapy recently showed to be effective compared to standard chemotherapy. First-line therapy brentuximab vedotin-CHP for sALCL was recently approved in Italy following the published 5-year data from the ECHELON-2 study. Correlations with biological parameters are missing.
Within the framework of the FIL, I...